EMA urgently reviewing multiple sclerosis medicine Zinbryta following cases of inflammatory brain disorders

View source ↗

Summary

EMA is urgently reviewing the multiple sclerosis medicine Zinbryta due to reported cases of inflammatory brain disorders.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Zinbryta (daclizumab high yield process)